Product Center
Received National-Level Recognition!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01
- Views:
(Summary description)Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
Received National-Level Recognition!
(Summary description)Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-01 16:18
- Views:
Recommended by provincial adverse drug reaction monitoring institutions and evaluated by the National Center for Adverse Drug Reaction Monitoring, Ab&B Bio-Tech Co., Ltd. JS demonstrated outstanding performance in fulfilling its primary responsibilities for adverse drug reaction monitoring in 2023 and was commended by the National Center.
This recognition reflects the affirmation of Ab&B Bio-Tech Co., Ltd. JS's preliminary work by monitoring institutions at all levels. The company will cherish this honor, continue to implement the "four strictest" requirements and General Secretary Xi Jinping's directives on drug safety, and enhance pharmacovigilance capabilities to safeguard public health.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
